Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report issued on Thursday, Briefing.com reports. The brokerage set a “neutral” rating on the stock.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $11.30 on Thursday. The stock’s 50-day moving average price is $9.29 and its two-hundred day moving average price is $11.24. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $34.46.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($14.07) earnings per share for the quarter, missing the consensus estimate of ($6.70) by ($7.37). On average, research analysts forecast that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Logos Global Management LP acquired a new position in Avalo Therapeutics in the second quarter valued at about $6,722,000. Ikarian Capital LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $1,015,000. Finally, Affinity Asset Advisors LLC increased its stake in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.